St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
The Cytogenetics shared resource supports laboratory-based research and conducts various cytogenetic analyses with the mission to guide risk-directed cancer therapies.
The Cytogenetic Shared Resource provides essential expertise and cutting-edge equipment to scientists across the institution. This resource enables researchers to design, build, and utilize cell-based genetic assays, allowing them to directly visualize newly discovered genetic events contributing to cancer biology within individual cells. By observing the genome in its natural cellular environment, researchers can gain unique insights that might otherwise be overlooked. Our experienced cytogenetic staff collaborates with scientists throughout St. Jude, advancing research goals through their specialized knowledge and techniques.
The Cytogenetic Shared Resource has contributed to numerous groundbreaking discoveries, including the initial cloning of the ALK gene, uncovering novel mechanisms of oncogene activation through analysis of 3D chromatin dynamics, and investigating the formation of transcription condensates in cancer. Our capabilities extend beyond traditional cytogenetics to include immunofluorescence protein staining combined with both RNA and DNA FISH, which can be applied to cells from both culture and tissue samples.
The resource is uniquely positioned to enhance understanding of transcription processes and identify potential intervention points to control individual gene expression. This work contributes significantly to advancing cancer research and potential treatment strategies at St. Jude. Through our collaborative approach and state-of-the-art techniques, we continue to play a crucial role in the institution's mission to combat childhood diseases.
The cytogenetic core team has shown enormous research experience and are highly motivated to apply the most appropriate cutting-edge research tools to my research work. I really enjoy the close collaboration and science brainstorming with this team in the past years.
Chunliang Li, Assistant Member
Dr. Steven Burden earned his PhD in Biomolecular Sciences from Boise State University, where his research was focused on the study and engineering of novel fluorogenic RNA structures. Leveraging the technological advancements from his doctoral studies, he founded a company in early 2019. The company's mission was to provide rapid and accurate diagnostics to individuals, irrespective of their socioeconomic background. Dr. Burden is driven to enhance the field with cutting-edge tools, particularly in genetically encodable fluorogenic RNA tracking, demonstrating his commitment to advancing the frontiers of research and diagnostics.
Steven Burden, PhD
Director
Virginia Valentine
Lead-Researcher
Seth Staller, PhD
Lead-Researcher
Julia Wilbourne
Lead-Researcher